Encouraging developments included an opportunity to build on the blockbuster debut of GSK’s RSV vaccine and the potential return of a previously withdrawn cancer drug.
Gilead invests $320M in Arcus to increase stake to 33%
The deal, which includes an upfront commitment from AstraZeneca as well as funding and milestone payments, marks the latest sign of Big Pharma’s confidence in AI-fueled R&D.
AbbVie to acquire ADC manufacturer ImmunoGen for $10.1B in oncology play
The ImmunoGen deal, which is expected to close in the middle of 2024, is also estimated to be accretive to AbbVie’s diluted earnings per share beginning in 2027.
Gilead Oncology’s brand refresh takes back the possibilities cancer steals
Amgen Partners of Choice will comprise eight medical institutions worldwide, including the Dana-Farber Cancer Institute in Boston and Gustave Roussy in Paris.
Amgen Oncology documents Patient Points of View in video series